Breaking Research News from sources other than Breastcancer.org
Comments
-
Roche Adapts Newer Breast Cancer Drug in Face of Herceptin Imitations
Roche aims to broaden the use of Kadcyla (ado-trastuzumab emtansine) for breast cancer as rivals crowd into the market with biosimilar copies of its older mainstay Herceptin (trastuzumab).
Roche said on Tuesday it had applied for U.S. Food and Drug Administration approval for Kadcyla, a five-year-old drug, for post-surgical use in women with a form of early stage breast cancer who still show signs of disease after treatment with Herceptin and chemotherapy.
"With Kadcyla, the approximately 60 percent share of sales generated by Herceptin as an adjuvant would be secured for several years..."
Of people treated with Kadcyla, 88.3 percent did not see their breast cancer return after three years - compared to 77 percent treated after surgery with Herceptin - according to a clinical study Roche is using to underpin its approval case with the FDA.
The FDA has granted the medicine a speedy review, Roche said, pointing to a decision in coming months.
-
Half a Million Breast Cancer Deaths Avoided in Last 30 Years
Encouraging Statistics Are a Result of Improved Treatment and Screening
Progress in both detection and management of breast cancer may have saved the lives of hundreds of thousands of women over the past three decades, according to a new report.
https://www.medscape.com/viewarticle/908920#vp_1
https://onlinelibrary.wiley.com/doi/epdf/10.1002/c...
Cancer 2019;0:1-7
-
Calif. Physician Indicted in Alleged Cancer Drug Scam
Benedict Liao, MD, was featured in earlier MedPage Today investigation
by John Fauber, Reporter, Milwaukee Journal Sentinel/MedPage TodayFebruary 08, 2019
A physician who was the subject of a 2018 Milwaukee Journal Sentinel/MedPage Todayinvestigation has been indicted by federal prosecutors as part of an alleged $1.6-million scheme to sell an unapproved cancer drug to patients around the country.
https://www.medpagetoday.com/publichealthpolicy/et...
-
iMedicalApps: Medicare's 'What's Covered' Review
Unravel the mysteries of Medicare on your mobile device
In January, the Centers for Medicare and Medicaid Services (CMS) launched a new app called "What's covered." The app takes some of the most popular information from the Medicare website and puts it in the palm of patients and providers hands via an intuitive app.
The primary focus for the app is on the common "what's covered" preventive services questions....The app contains key information on both Part A and Part B coverage and the prices for what is/isn't covered in those two areas....The app emphasizes those preventive services that are or are not covered (such as USPSTF recommendations) and both hospital and outpatient information. All data is available on the Medicare website, but the app is more user-friendly regarding Medicare -- what's covered.
https://www.medpagetoday.com/blogs/iltifathusain/7...
-
'Remarkable' New Benefit in HER2+ Breast Cancer
KATHERINE and T-DM1 Change Practice
https://www.medscape.com/viewarticle/909055?src=wn...
{More on the results of the KATHERINE trial - clearer coverage of some aspects of the trial, IMHO.}
The trial enrolled patients with stage I to III HER2-positive disease who were found to have residual disease upon excision after standard neoadjuvant treatment (chemotherapy plus a HER2-targeted drug). The trialists randomized these patients to post-surgery ado-trastuzumab emtansine (T-DM1; Kadcyla, Roche) or the current adjuvant standard — trastuzumab — for 14 cycles.
-
Chocolate Fights Coughs Better Than Codeine, Says Science
https://www.coastalliving.com/food/chocolate-cures...
Good news for chocoholics. The next time you come down with a cough, just pop a piece of your favorite treat and you'll get all the cough-suppressing effects of codeine syrup without the fuzzy-headed side-effects. Here's how it works.
{To quote the contact who sent me this link "a friend sent me this article. I have prudently decided to accept the conclusion without evaluating the scientific evidence
" Chocolate is my favorite therapy.} -
Cancer Drug Has Money-Back Guarantee — in China
Palbociclib Refund Not Available in US
In China, Pfizer will reimburse up to 33% of the cost of its breast cancer drug palbociclib (Ibrance) if a patient's disease progresses within 4 months...
https://www.medscape.com/viewarticle/909138?src=wn...
-
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer and Outcomes Based on COX-2 Expression and ER Status
Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors. COX-2 inhibitors should preferably be avoided during docetaxel use in patients with breast cancer who are undergoing neoadjuvant chemotherapy (NAC).
Journal of Clinical Oncology
https://www.practiceupdate.com/C/79231/56?elsca1=e...
DOI: 10.1200/JCO.18.00636 Journal of Clinical Oncology
-
Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
- Patients with stage II/III, ER-negative, HER2-positive breast cancer treated with four cycles of neoadjuvant pertuzumab and trastuzumab were followed to evaluate the correlation between early measurements of tumor maximum standardized uptake values corrected for lean body mass (SULmax) on PET/CT and pathologic complete response (pCR). Compared with patients who did not obtain pCR, those who did had a greater reduction in SULmax by day 15, a higher prevalence of SULmax reduction ≥40%, and a higher proportion of day 15 SULmax ≤3.
- Early changes in SULmax predict the response to adjuvant pertuzumab/trastuzumab among patients with ER-negative, HER2-positive breast cancer. The use of this imaging strategy may eventually facilitate the use of targeted therapy.
Early changes in SULmax predict response to four cycles of PT in estrogen receptor-negative, HER2-positive breast cancer. Once optimized, this quantitative imaging strategy may facilitate a more tailored approach to therapy in this setting.
Journal of Clinical Oncology
https://www.practiceupdate.com/C/79480/56?elsca1=e...
DOI: 10.1200/JCO.2018.78.7986 Journal of Clinical Oncology
-
Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients With Solid Tumors Receiving Chemotherapy
- The authors of this phase II/III observer-blind, multicenter study report the immunogenicity and safety of the recombinant zoster vaccine (RZV) given to 232 patients with solid tumors before or at the initiation of a chemotherapy cycle. Patients given the RZV vaccine had higher postvaccination anti-gE antibody concentrations, gE-specific CD4+ T-cell frequencies, and vaccine response rates compared with patients given placebo. Adverse events occurred more frequently in the RZV group compared with the placebo group.
- The use of RZV in patients with solid tumors receiving immunosuppressive chemotherapies was associated with a durable humoral and cell-mediated immune response without the development of any new safety concerns.
- RZV was immunogenic in patients with STs receiving immunosuppressive chemotherapies. Humoral and cell-mediated immune responses persisted 1 year after vaccination. No safety concerns were identified.
- data are emerging that RZV is both immunogenic and safe in solid tumor patients vaccinated before or during chemotherapy. If validated in other groups of immunocompromised patients, this would represent a significant advance in cancer care.
- https://www.practiceupdate.com/content/immunogenic...
- https://onlinelibrary.wiley.com/doi/full/10.1002/c...
- https://doi.org/10.1002/cncr.31909
-
Tucatinib With T-DM1 for HER2-Positive Metastatic Breast Cancer
Interview with Alison K Conlin MD Interview by Farzanna S Haffizulla MD, FACP, FAMWA
https://www.practiceupdate.com/content/tucatinib-w...
Re: a recent study looking at tucatinib in combination with T-DM1 for patients with HER2-positive breast cancer. Results were quite promising "both in the body and in central nervous system metastases."
-
Impact of Metastatic Pattern on the Prognosis in Stage IV Breast Cancer at Initial Diagnosis
- Using data from the SEER program from 2010 to 2013, this study evaluated 9143 women with stage IV breast cancer at initial diagnosis to determine factors associated with specific sites of metastases. Of these patients, 37.5% had bone metastases and a median overall survival of 38 months; 21.9% had visceral metastases and a median overall survival of 21 months; 28.8% had bone and visceral metastases and a median overall survival of 19 months; and 11.9% had other metastases and a median overall survival of 33 months. Older age, black race, grade 3/4 tumors, triple-negative disease, bone and visceral metastases, and an unmarried status were associated with significantly shorter overall survival. Patients with triple-negative and ER−/HER2+ disease were more likely to have brain, liver, lung, and other metastases, while patients with ER+/HER2+ disease were more likely to have liver metastases.
- These findings demonstrate significant differences in survival based on specific sites of metastases that are influenced by tumor subtypes, which may be used to guide therapeutic choices for these patients.
- https://www.practiceupdate.com/content/impact-of-m...
- https://link.springer.com/article/10.1007%2Fs10549...
- Leone, B.A., Vallejo, C.T., Romero, A.O. et al. Breast Cancer Res Treat (2017) 161: 537. https://doi.org/10.1007/s10549-016-4066-7
-
Everolimus/Lapatinib/Capecitabine Is Effective and Safe for HER2+ Breast Cancer With Brain Metastases
- Results of this study demonstrate the tolerability of the combination of everolimus, lapatinib, and capecitabine in heavily pretreated patients with HER2-positive disease and brain metastasis.
- Given the promising response rate (27% at 12 weeks), additional larger studies are warranted.
- https://www.practiceupdate.com/c/77979/67/13/?elsc...
- https://journals.sagepub.com/doi/10.1177/175883591...
- https://doi.org/10.1177/1758835918807339
-
New cell-tracking technique sheds light on breast cancer spread
Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer | Nature Communications
-
November 28, 2018
Statins Repurposed to Slow Proliferation in Metastatic Breast Cancer Cells
The findings suggest the consideration of long-term use of statins for patients with breast cancer.Statins were shown to slow proliferation in metastatic breast cancer cells but not primary tumor cells, suggesting the long-term use of statins in the adjuvant setting should be considered for patients with breast cancer.1 Statins have been found to reduce mortality in patients with breast cancer, but the mechanism by which statins influence mortality without affecting the growth of the primary tumor has been unclear. The study results were recently published in the British Journal of Cancer.
To elucidate the effect of statins on metastatic cell proliferation, study researchers created several models to mimic breast cancer metastasis. In vitro and ex vivo models were created to mimic breast cancer metastasis to the liver. The in vitro model was a 2-dimensional coculture, and the ex vivo model was a 3-dimensional microphysiological system. Two independent mouse models were created to mimic spontaneous breast cancer metastasis to the lung and liver.
Statins were shown in each model to "directly affect the proliferation of breast cancer cells, specifically at the metastatic site," the study authors wrote. In the in vitro model, atorvastatin slowed proliferation of mesenchymal but not epithelial breast cancer cells. When dormant breast cancer cells were stimulated in the 3-dimensional ex vivo microphysiological system, atorvastatin inhibited their emergence. In both mouse models, statins slowed proliferation of metastatic cells but not primary tumor cells.
RELATED ARTICLES
- Liquid Biopsy as a Surveillance Tool for Breast Cancer Follow-Up
- Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype
- Higher Sensitivity With 1-View Digital Breast Tomosynthesis for Breast Cancer Detection
"As statins can block metastatic tumor outgrowth, they should be considered for use as long-term adjuvant drugs to delay clinical emergence and decrease mortality in breast cancer patients," the study authors concluded.
Reference
- Beckwitt CH, Clark AM, Ma B, Whaley D, Oltvai ZN, Wells A. Statins attenuate outgrowth of breast cancer metastases. Br J Cancer. 2018;119(9):1094-1105. doi: 10.1038/s41416-018-0267-7
-
p, p'-DDT Exposure Linked to Breast Cancer Through Age 54
Risk for breast cancer varies based on timing of first exposure, age at diagnosis
"Considering the patterns we observed, working backward to determine when a woman first came into contact with the chemical could help inform early detection and treatment of DDT-associated breast cancer,"
study published online Feb. 13 {2019} in the Journal of the National Cancer Institute.
-
Researchers Develop Therapy to Fight Blood Clots and Cancer Metastasis
A preclinical study of deactivated platelets promises new approach to treating diseases.
https://gwtoday.gwu.edu/researchers-develop-therap...
A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent the spread of cancer cells from a primary site to different parts of the body—or cancer metastasis, according to a study published Wednesday in Science Translational Medicine.
"our results suggest that platelet decoys might represent an effective strategy for obtaining antithrombotic and antimetastatic effects."
http://stm.sciencemag.org/content/11/479/eaau5898
DOI: 10.1126/scitranslmed.aau5898
-
Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype
- This population-based cohort study was designed to evaluate the influence of various systemic treatment regimens on the subtype-specific risk of contralateral breast cancer (CBC). The 10-year cumulative incidence of CBC was 3.8%. Endocrine therapy, adjuvant chemotherapy, and trastuzumab with chemotherapy were associated with a reduced risk of CBC. Taxane-containing chemotherapy and aromatase inhibitors were associated with the largest reduction in CBC risk.
- The risk of CBC is reduced in association with endocrine therapy, chemotherapy, and trastuzumab with chemotherapy, and each regimen has varying effects on CBC subtypes. The biggest reduction in risk is seen following treatment with taxane-containing chemotherapy and aromatase inhibitors.
- Of 83,144 BC patients, 2,816 developed a CBC; the 10-year cumulative incidence was 3.8%
-
Broad Institute targets blood-draw diagnostics
FEBRUARY 19, 2019
With pledges of $25 million, the nonprofit Broad Institute of MIT and Harvard plans to announce Tuesday that it's creating a new center to develop a diagnostic test to pinpoint how well cancer patients respond to treatment through a simple blood draw.
Louis V. Gerstner Jr., the former CEO of IBM who chairs the institute's board of directors, has committed $15 million to the Gerstner Center for Cancer Diagnostics at the Broad. The center will receive an additional $10 million from the Eli and Edythe Broad Foundation.
The center is pursuing a goal that some other biotech companies in the United States are also chasing: developing a sensitive blood-based biopsy to speed cancer detection.
Although many aspects of cancer treatment have improved dramatically in recent years, diagnostic tests have lagged, according to Broad officials. Today, doctors still rely on a biopsy of a tumor obtained through surgery or have the patient undergo a CT or MRI scan. Surgical biopsies are invasive, of course, and the other tests provide no molecular insights.
The Gerstner Center will focus on developing a blood biopsy that would monitor a patient's response to chemotherapy, radiation, or immunotherapy with molecular precision. Broad scientists hope the test would identify small numbers of cancer cells that remain in patients who have been treated and may cause a relapse years or even decades later.
"Not long ago, I thought that blood biopsy was more science fiction than reality," said Dr. Todd Golub, a cancer specialist who works as Broad's chief scientific officer and will head the Gerstner Center. "In fact, Broad scientists have demonstrated that it's possible to look at an entire cancer genome from a blood biopsy. That is spectacular."
The new center will work with technology experts, cancer biologists, computational scientists, and clinicians.
-
Cancer treatment at home is safe, effective, and closer to happening than you think
Imagine having cancer and being told that most of your treatment will happen in your home instead of a high-tech cancer center. That may sound preposterous, but it's closer to happening than you might think.
The cancer care at home model could become a reality...
It's time to reimagine the role of hospitals and outpatient clinics in cancer care. Rather than being the routine site of care, hospitals and outpatient clinics should be reserved for the minority of cancer patients who require treatments that only hospitals and clinics can give. People with cancer will thank us for this change, from the comfort of their homes.
https://www.statnews.com/2019/02/06/cancer-treatme...
-
People diagnosed with cancer often don't embrace the term 'survivor'
"Cancer survivor" has become a catch-all phrase to refer to living individuals diagnosed with cancer at some point in their lives. Cancer clinics and clinicians, patient advocacy organizations and media reportscommonly use the term.
Should the same term be used for the entire spectrum of living people who have experienced cancer, which represents more than 100 distinct diseases affecting approximately 14 million people in the United States?
An analysis of 23 studies of how people diagnosed with cancer view the term "cancer survivor" shows that although many embrace it, others see it as inappropriate.
Language used with and about patients is important and can cause needless distress when used without care.
Conclusions: Using the blanket term "survivor" to label a diverse group is problematic; although the term offers a positive identity for some, others reject it or find it offensive, at least for patients like those represented in this study. If cancer patients are going to be labeled, they should choose the one that is most empowering and reflective of their experience.
https://theconversation.com/people-diagnosed-with-...
https://www.tandfonline.com/doi/abs/10.1080/073473...
-
Increasing the Dose Intensity of Chemotherapy by More Frequent Administration or Sequential Scheduling
- The Lancet This meta-analysis was designed to compare the impact of dose-intense versus standard-schedule chemotherapy for patients with early breast cancer. The risk of recurrence at 10 years was lower in the dose-intense group compared with the standard-schedule group (28.0% vs 31.4%; P<.0001). Both 10-year breast cancer mortality and all-cause mortality were also significantly lower in the dose-intense group compared with the standard-schedule group.The use of dose-intense chemotherapy for patients with breast cancer appears to reduce the risk of recurrence and cancer death.Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles, or by giving individual drugs sequentially rather than giving the same drugs concurrently, moderately reduces the 10-year risk of recurrence and death from breast cancer without increasing mortality from other causes.https://www.practiceupdate.com/C/79928/56?elsca1=e...https://linkinghub.elsevier.com/retrieve/pii/S0140...DOI:https://doi.org/10.1016/S0140-6736(18)33137-4
-
Pembrolizumab Plus Trastuzumab in Trastuzumab-Resistant, Advanced HER2-Positive Breast Cancer
PANACEA: a single-arm, multicentre, phase 1b–2 trial
- The Lancet Oncology TAKE-HOME MESSAGEThis phase Ib/II trial was designed to evaluate the activity of pembrolizumab plus trastuzumab among patients with trastuzumab-resistant advanced HER2-positive breast cancer. In the phase II cohort, there was an objective response rate of 15% among PD-L1–positive patients but no responses in PD-L1–negative patients.Pembrolizumab plus trastuzumab appears to have some activity against PD-L1–positive, HER2-positive breast cancer, and further studies are needed to confirm these findings.HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastuzumab-resistant, advanced HER2-positive breast cancer.Pembrolizumab plus trastuzumab was safe and showed activity and durable clinical benefit in patients with PD-L1-positive, trastuzumab-resistant, advanced, HER2-positive breast cancer. Further studies in this breast cancer subtype should focus on a PD-L1-positive population and be done in less heavily pretreated patients.https://www.practiceupdate.com/C/79904/56?elsca1=e...https://www.thelancet.com/journals/lanonc/article/...(18)30812-X/fulltextDOI:https://doi.org/10.1016/S1470-2045(18)30812-X
-
CONCLUSION
“Compared with women, men with HR+/HER2+ tumors had twice the risk of death.
Objectives: To analyze differences in overall survival(OS) between male breast cancer (MBC) and female breast cancer (FBC) according to tumor subtype compared with other factors.
Materials and Methods: We evaluated men and women with breast cancer between 2010 and 2013 with known hormone receptor (HR) status and human epidermal growth factor receptor 2 (HER2) status reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Patient characteristics were compared between groups. Univariate and multivariate analyses were performed to determine the effect of each variable on OS. Breast cancer–specific survival was a secondary endpoint.
Results: We included 1187 MBC and 166,054 FBC. Median follow-up was 21 months (range, 1 to 48) for both groups. OS at 3 years for MBC and FBC was 85.6% and 90.4%, respectively (P=0.0002). MBC were more ductal, had higher grade, presented with more advanced stage and were often HR+/HER2− (each P<0.0001). MBC had worse OS than FBC in HR+/HER2− (Hazard ratio [HaR], 1.5; P=0.0005), HR+/HER2+ (HaR, 2.8; P<0.0001) and triple negative (HaR, 4.3; P<0.0001) (P interaction<0.02). MBC had significantly worse OS than FBC in stages I and II, but similar OS in stages III and IV (P interaction<0.01). In multivariate analysis, HR+/HER2+ was the only subtype with significant differences in OS between MBC and FBC (HaR, 2.0; P=0.002).
Conclusions: OS was significantly different in both groups. Men had worse OS in early stages while similar OS in stages III and IV. There were significant differences in OS according to tumor subtype; compared with women, men with HR+/HER2+ tumors had twice the risk of death.
-
Oncotype DX Not Cost-Effective for Low-Risk Breast Cancer
Incremental cost-effectiveness ratio varies across clinical risk groups, sensitive to patient age
The multigene expression test Oncotype DX (ODX) is not cost-effective for women with breast cancer who are at low risk for recurrence, according to research published online Jan. 22 in the Journal of the National Comprehensive Cancer Network.
"ODX is not cost-effective for women with clinical low-risk breast cancer, which constitutes most patients with ER-positive disease," the authors write.
https://www.practiceupdate.com/C/80064/56?elsca1=e...
http://www.jnccn.org/content/17/1/39.full?sid=4a3a...
doi:10.6004/jnccn.2018.7077
-
Hepatic Arterial Therapy With Oxaliplatin and Systemic Capecitabine for Liver Metastases From Breast Cancer
- The authors report the results of two phase II trials investigating the combination of capecitabine and oxaliplatin in patients with breast cancer and liver metastases. Among the 52 patients, the response rate was 42.3%, including 7.7% complete responses and 34.6% partial responses. The median progression-free survival was 10.8 months. The most frequently reported grade 3 adverse events were hand–foot syndrome, neuropathy, fatigue, and abdominal pain.
- The results demonstrate that the combination of capecitabine and oxaliplatin is effective and well-tolerated in patients with breast cancer liver metastases.
Commentary by Lillie D Shockney RN, BS, MASOne challenge of a patient who has liver metastasis is that she needs her liver to be metabolizing properly in order for chemotherapy—really any systemic treatments—to work as intended. The approach reported here appears to bypass the usual method of administration, and the drug is placed directly in the liver itself. The numbers are small, but the results are promising. The treatment schedule can be tricky and will require close monitoring, follow-up, and specific points of contact throughout the treatment process.
These women are paving the ways for future women diagnosed after them. {Gratuitous comment by poster: Many of us are grateful!}
https://www.thebreastonline.com/article/S0960-9776(18)30331-X/fulltext -
The role of histone deacetylase inhibitors in metastatic breast cancer
{This sounds fairly cutting edge and technical, but for those who like to be ahead of the curve/keep up with the latest research, I thought I would put this early report out there....}
Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.
https://www.practiceupdate.com/c/77977/67/13/?elsc...
https://www.thebreastonline.com/article/S0960-9776(18)30330-8/fulltext
DOI: https://doi.org/10.1016/j.breast.2018.12.001
{This is a pay-per-article unless you have access to a research database.}
-
The role of histone deacetylase inhibitors in metastatic breast cancer
{This sounds fairly cutting edge and technical, but for those who like to be ahead of the curve/keep up with the latest research, I thought I would put this early report out there....}
Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.
https://www.practiceupdate.com/c/77977/67/13/?elsc...
https://www.thebreastonline.com/article/S0960-9776(18)30330-8/fulltext
DOI: https://doi.org/10.1016/j.breast.2018.12.001
{This is a pay-per-article unless you have access to a research database.}
-
'Not Letting It Define Us' — Walking The Runway With Metastatic Breast Cancer
https://www.npr.org/sections/health-shots/2019/02/...
{This isn't technically research news but I thought some people might be interested in this news coverage of MBC....}
....This was the third annual #Cancerland fashion show, put on by METAvivor, a nonprofit organization that supports research and awareness of metastatic breast cancer, along with lingerie company, AnaOno. The goal: Raise funds for research to improve treatment for metastatic disease, while changing public perception of the condition.
-
New recommendations say not all women need genetic testing for cancer. Critics say it could cost lives
CNNPrimary care providers should screen women for personal, family and/or ethnic history of breast, ovarian, tubal or peritoneal cancer to decide who should undergo genetic counseling for BRCA1 and BRCA2 mutations, the US Preventive Services Task Force recommended Tuesday. The mutations increase a woman's cancer risk. Read the full story
Shared from Apple News
Categories
- All Categories
- 679 Advocacy and Fund-Raising
- 289 Advocacy
- 68 I've Donated to Breastcancer.org in honor of....
- Test
- 322 Walks, Runs and Fundraising Events for Breastcancer.org
- 5.6K Community Connections
- 282 Middle Age 40-60(ish) Years Old With Breast Cancer
- 53 Australians and New Zealanders Affected by Breast Cancer
- 208 Black Women or Men With Breast Cancer
- 684 Canadians Affected by Breast Cancer
- 1.5K Caring for Someone with Breast cancer
- 455 Caring for Someone with Stage IV or Mets
- 260 High Risk of Recurrence or Second Breast Cancer
- 22 International, Non-English Speakers With Breast Cancer
- 16 Latinas/Hispanics With Breast Cancer
- 189 LGBTQA+ With Breast Cancer
- 152 May Their Memory Live On
- 85 Member Matchup & Virtual Support Meetups
- 375 Members by Location
- 291 Older Than 60 Years Old With Breast Cancer
- 177 Singles With Breast Cancer
- 869 Young With Breast Cancer
- 50.4K Connecting With Others Who Have a Similar Diagnosis
- 204 Breast Cancer with Another Diagnosis or Comorbidity
- 4K DCIS (Ductal Carcinoma In Situ)
- 79 DCIS plus HER2-positive Microinvasion
- 529 Genetic Testing
- 2.2K HER2+ (Positive) Breast Cancer
- 1.5K IBC (Inflammatory Breast Cancer)
- 3.4K IDC (Invasive Ductal Carcinoma)
- 1.5K ILC (Invasive Lobular Carcinoma)
- 999 Just Diagnosed With a Recurrence or Metastasis
- 652 LCIS (Lobular Carcinoma In Situ)
- 193 Less Common Types of Breast Cancer
- 252 Male Breast Cancer
- 86 Mixed Type Breast Cancer
- 3.1K Not Diagnosed With a Recurrence or Metastases but Concerned
- 189 Palliative Therapy/Hospice Care
- 488 Second or Third Breast Cancer
- 1.2K Stage I Breast Cancer
- 313 Stage II Breast Cancer
- 3.8K Stage III Breast Cancer
- 2.5K Triple-Negative Breast Cancer
- 13.1K Day-to-Day Matters
- 132 All things COVID-19 or coronavirus
- 87 BCO Free-Cycle: Give or Trade Items Related to Breast Cancer
- 5.9K Clinical Trials, Research News, Podcasts, and Study Results
- 86 Coping with Holidays, Special Days and Anniversaries
- 828 Employment, Insurance, and Other Financial Issues
- 101 Family and Family Planning Matters
- Family Issues for Those Who Have Breast Cancer
- 26 Furry friends
- 1.8K Humor and Games
- 1.6K Mental Health: Because Cancer Doesn't Just Affect Your Breasts
- 706 Recipe Swap for Healthy Living
- 704 Recommend Your Resources
- 171 Sex & Relationship Matters
- 9 The Political Corner
- 874 Working on Your Fitness
- 4.5K Moving On & Finding Inspiration After Breast Cancer
- 394 Bonded by Breast Cancer
- 3.1K Life After Breast Cancer
- 806 Prayers and Spiritual Support
- 285 Who or What Inspires You?
- 28.7K Not Diagnosed But Concerned
- 1K Benign Breast Conditions
- 2.3K High Risk for Breast Cancer
- 18K Not Diagnosed But Worried
- 7.4K Waiting for Test Results
- 603 Site News and Announcements
- 560 Comments, Suggestions, Feature Requests
- 39 Mod Announcements, Breastcancer.org News, Blog Entries, Podcasts
- 4 Survey, Interview and Participant Requests: Need your Help!
- 61.9K Tests, Treatments & Side Effects
- 586 Alternative Medicine
- 255 Bone Health and Bone Loss
- 11.4K Breast Reconstruction
- 7.9K Chemotherapy - Before, During, and After
- 2.7K Complementary and Holistic Medicine and Treatment
- 775 Diagnosed and Waiting for Test Results
- 7.8K Hormonal Therapy - Before, During, and After
- 50 Immunotherapy - Before, During, and After
- 7.4K Just Diagnosed
- 1.4K Living Without Reconstruction After a Mastectomy
- 5.2K Lymphedema
- 3.6K Managing Side Effects of Breast Cancer and Its Treatment
- 591 Pain
- 3.9K Radiation Therapy - Before, During, and After
- 8.4K Surgery - Before, During, and After
- 109 Welcome to Breastcancer.org
- 98 Acknowledging and honoring our Community
- 11 Info & Resources for New Patients & Members From the Team